Search results
Results from the WOW.Com Content Network
The single submission process for approval to conduct research in all EU member states is facilitated by the Clinical Trials Information System (CTIS). [3] CTIS is an online portal which enables interactions between clinical trial sponsors (that is, the organization responsible for the conduct of the clinical trial), and the regulatory ...
Abbrev. [1]Meaning [1] Latin (or Neo-Latin) origin [1]; a.c. before meals: ante cibum a.d., ad, AD right ear auris dextra a.m., am, AM morning: ante meridiem: nocte ...
q.a.d. every other day (from Latin quaque altera die) QALY: quality-adjusted life year: q.AM: every day before noon (from Latin quaque die ante meridiem) q.d. every day (from Latin quaque die) q.d.s. four times each day (from Latin quater die sumendus) q.h. each hour (from Latin quaque hora) q.h.s. every bedtime (from Latin quaque hora somni) q ...
The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate and partial agreement of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia (an international treaty adopted by the Council of Europe in 1964: ETS 50, [2] Protocol [3]).
In the 1980s, the European Union began harmonising regulatory requirements. In 1989, Europe, Japan, and the United States began creating plans for harmonisation. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990 at a meeting in Brussels.
A question and answer system (or Q&A system) is an online software system that attempts to answer questions asked by users.Q&A software is frequently integrated by large and specialist corporations and tends to be implemented as a community that allows users in similar fields to discuss questions and provide answers to common and specialist questions.
In January 2024, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L. [5] In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone. [5]
Q&A was a database and word processing software program for IBM PC–compatible computers published by Symantec and partners from 1985 to 1998. It was written by a team headed by Symantec founder Dr. Gary Hendrix , [ 1 ] [ 2 ] Denis Coleman, and Gordon Eubanks .